The independent medical news service
07-06-2022 | Oncology | News | Article
ENZAMET update confirms benefits of add-on enzalutamide
An updated analysis of the ENZAMET trial confirms earlier findings that adding enzalutamide to testosterone suppression provides statistically and clinically meaningful survival improvements in metastatic hormone-sensitive prostate cancer.